Trial Profile
A Randomised, Double-blind, Parallel-group, Placebo Controlled Study of Esomeprazole i.v. (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour) Administered for 72 Hours to Assess Prevention of Rebleeding in Subjects That Have Undergone Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer - the PUB Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs Esomeprazole (Primary) ; Esomeprazole (Primary)
- Indications Bleeding ulcer; Gastrointestinal haemorrhage
- Focus Therapeutic Use
- Acronyms PUB
- Sponsors AstraZeneca
- 17 Jan 2017 Results of post hoc multivariable analyses published in the American Journal of Gastroenterology.
- 30 May 2009 Results presented at DDW 2009.
- 24 Apr 2009 Results have been reported in the Annals of Internal Medicine.